Nasdaq · CIK 0000874716 · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
IDEXX LABORATORIES INC /DE
IDXX chart by TradingView
PRICE HISTORY
LIVE · NASDAQIDXX chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $4.3B
- EBITDA
- $1.5B
- FREE CASH FLOW
- $1.1B
- EPS
- $13.08
- GROSS MARGIN
- 61.80%
- ROIC
- 56.50%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
36.6x
-24%36.6x76.5x
⤢
P / SALES (TTM)
9.2x
+55%5.9x18.0x
⤢
P / BOOK
25.9x
-86%21.5x379.7x
⤢
EV / EBITDA (TTM)
26.0x
+0%26.0x57.5x
⤢
EV / REVENUE (TTM)
9.2x
+47%6.3x18.2x
⤢
FCF YIELD (TTM)
3.00%
+0.5pp1.09%3.00%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$1.2B
+171%⤢
EBITDA (DERIVED)
$0.5B
+331%⤢
NET INCOME
$0.3B
+499%⤢
EPS (DILUTED)
$4.27
+589%⤢
REVENUE GROWTH YOY
9.66%
-0.7pp2.82%29.57%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
26.51%
+6.8pp-3.37%33.59%
⤢
RETURN ON CAPITAL
61.09%
-6.1pp42.58%80.48%
⤢
RETURN ON EQUITY (TTM)
70.67%
-319.5pp53.51%756.88%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN64.04%
OPERATING MARGIN34.98%
NET MARGIN27.82%
FCF MARGIN26.51%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.3B
+266%⤢
STOCK-BASED COMP
$0.0B
+216%⤢
CAPITAL EXPENDITURE
$0.0B
+104%⤢
SHARES OUTSTANDING
0.08B
-13%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.2B
+31%⤢
TOTAL DEBT
$0.4B
-24%⤢
DEBT / EBITDA (TTM)
0.3x
-80%0.3x1.4x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 96.27%INSIDERS 0.22%OTHER / RETAIL 3.51%1,841 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 10.62% | 8.4M | $4.91B | -2.0% |
| Vanguard Capital Management LLC | 6.58% | 5.2M | $3.04B | NEW |
| Vanguard Portfolio Management LLC | 4.96% | 3.9M | $2.29B | NEW |
| State Street Corporation | 4.66% | 3.7M | $2.16B | +0.5% |
| Invesco Ltd. | 4.25% | 3.3M | $1.97B | +1.6% |
| Geode Capital Management, LLC | 3.38% | 2.7M | $1.56B | +3.0% |
| BAMCO Inc. | 2.07% | 1.6M | $958.2M | -9.2% |
| Fundsmith LLP | 1.86% | 1.5M | $859.9M | -21.9% |
| Morgan Stanley | 1.67% | 1.3M | $772.0M | -15.3% |
| Bank Of New York Mellon Corporation | 1.51% | 1.2M | $700.1M | -20.7% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.